David Jayne

78.4k total citations · 18 hit papers
520 papers, 32.2k citations indexed

About

David Jayne is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Genetics. According to data from OpenAlex, David Jayne has authored 520 papers receiving a total of 32.2k indexed citations (citations by other indexed papers that have themselves been cited), including 378 papers in Pulmonary and Respiratory Medicine, 291 papers in Rheumatology and 151 papers in Genetics. Recurrent topics in David Jayne's work include Vasculitis and related conditions (374 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (138 papers) and Otitis Media and Relapsing Polychondritis (119 papers). David Jayne is often cited by papers focused on Vasculitis and related conditions (374 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (138 papers) and Otitis Media and Relapsing Polychondritis (119 papers). David Jayne collaborates with scholars based in United Kingdom, United States and Sweden. David Jayne's co-authors include Raashid Luqmani, Rachel Jones, Kerstin Westman, Niels Rasmussen, Charles D. Pusey, Michael Walsh, C M Lockwood, Peter A. Merkel, Oliver Floßmann and Kenneth G. C. Smith and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

David Jayne

496 papers receiving 31.4k citations

Hit Papers

Rituximab versus Cyclophosphamide in ANCA-Associated Rena... 2003 2026 2010 2018 2010 2003 2008 2009 2007 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
    2010 1.1k citations Rachel Jones, Raashid Luqmani et al. profile →
  2. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
    2003 902 citations David Jayne, Niels Rasmussen et al. profile →
  3. Modification and validation of the Birmingham Vasculitis Activity Score (version 3)
    2008 794 citations Oliver Floßmann, David Jayne et al. Annals of the Rheumatic Diseases profile →
  4. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis
    2009 734 citations David Jayne et al. Journal of the American Society of Nephrology profile →
  5. Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis
    2007 706 citations David Jayne, Niels Rasmussen et al. Journal of the American Society of Nephrology profile →
  6. Long-term patient survival in ANCA-associated vasculitis
    2010 641 citations Oliver Floßmann, Lorraine Harper et al. Annals of the Rheumatic Diseases profile →
  7. EULAR recommendations for the management of primary small and medium vessel vasculitis
    2008 618 citations Bernhard Hellmich, David Jayne et al. Annals of the Rheumatic Diseases profile →
  8. Histopathologic Classification of ANCA-Associated Glomerulonephritis
    2010 580 citations David Jayne et al. Journal of the American Society of Nephrology profile →
  9. Avacopan for the Treatment of ANCA-Associated Vasculitis
    2021 548 citations David Jayne, Peter A. Merkel et al. profile →
  10. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody–associated vasculitis
    2005 513 citations Niels Rasmussen, Raashid Luqmani et al. profile →
  11. ANCA-associated vasculitis
    2020 499 citations Hans‐Joachim Anders, David Jayne et al. profile →
  12. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
    2015 481 citations David Jayne et al. profile →
  13. EULAR recommendations for the management of large vessel vasculitis
    2008 431 citations Bernhard Hellmich, David Jayne et al. Annals of the Rheumatic Diseases profile →
  14. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
    2011 421 citations David Jayne et al. profile →
  15. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis
    2017 420 citations David Jayne, Annette Bruchfeld et al. Journal of the American Society of Nephrology profile →
  16. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
    2022 130 citations David Jayne, Frédéric Houssiau et al. Annals of the Rheumatic Diseases profile →
  17. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
    2024 69 citations Parameswaran Nair, Benjamin Terrier et al. profile →
  18. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis
    2024 49 citations David Jayne, Vladimı́r Tesař et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Jayne United Kingdom 90 22.3k 14.5k 8.2k 7.4k 7.4k 520 32.2k
Peter A. Merkel United States 77 14.4k 0.6× 9.4k 0.6× 4.1k 0.5× 2.6k 0.4× 3.7k 0.5× 386 21.4k
Raashid Luqmani United Kingdom 61 13.3k 0.6× 7.8k 0.5× 3.9k 0.5× 2.3k 0.3× 2.3k 0.3× 296 16.1k
Ulrich Specks United States 62 10.2k 0.5× 5.0k 0.3× 2.9k 0.4× 2.3k 0.3× 2.3k 0.3× 302 13.9k
J. T. Lie United States 58 14.0k 0.6× 7.6k 0.5× 1.7k 0.2× 2.1k 0.3× 1.6k 0.2× 270 20.6k
John H. Stone United States 71 5.7k 0.3× 15.9k 1.1× 2.0k 0.2× 1.1k 0.1× 2.3k 0.3× 383 21.7k
Ming‐Hui Zhao China 58 5.0k 0.2× 3.6k 0.2× 1.6k 0.2× 5.9k 0.8× 4.8k 0.6× 545 13.4k
Robert W. Lightfoot United States 27 7.7k 0.3× 8.2k 0.6× 1.7k 0.2× 1.6k 0.2× 2.0k 0.3× 51 13.5k
E. William St. Clair United States 55 3.0k 0.1× 9.1k 0.6× 2.3k 0.3× 677 0.1× 5.3k 0.7× 170 16.5k
Munther A. Khamashta United Kingdom 84 2.5k 0.1× 22.6k 1.6× 1.1k 0.1× 3.5k 0.5× 10.1k 1.4× 411 31.3k
Luc Mouthon France 61 7.2k 0.3× 3.9k 0.3× 1.3k 0.2× 805 0.1× 2.7k 0.4× 389 13.2k

Countries citing papers authored by David Jayne

Since Specialization
Citations

This map shows the geographic impact of David Jayne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Jayne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Jayne more than expected).

Fields of papers citing papers by David Jayne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Jayne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Jayne. The network helps show where David Jayne may publish in the future.

Co-authorship network of co-authors of David Jayne

This figure shows the co-authorship network connecting the top 25 collaborators of David Jayne. A scholar is included among the top collaborators of David Jayne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Jayne. David Jayne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jayne, David. (2025). Emerging targeted therapies in ANCA-associated vasculitis. Lara D. Veeken. 64(Supplement_1). i15–i18. 2 indexed citations
2.
Merkel, Peter A., Parameswaran Nair, Nader Khalidi, et al.. (2025). Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases. 84(11). 1888–1899. 2 indexed citations
3.
Ivković, Vanja, Duvuru Geetha, Balazs Odler, et al.. (2025). WCN25-1022 LONG-TERM KIDNEY FUNCTION BEYOND 12 MONTHS AND KIDNEY RELAPSE AFTER INITIATION OF TREATMENT FOR ANCA-ASSOCIATED VASCULITIS. Kidney International Reports. 10(2). S617–S618. 1 indexed citations
4.
Richoz, Nathan, Zewen Kelvin Tuong, Georgina Bowyer, et al.. (2025). Temporal profiling of human lymphoid tissues reveals coordinated defense against viral challenge. Nature Immunology. 26(2). 215–229. 1 indexed citations
5.
Geetha, Duvuru, Christian Pagnoux, Sebastian E. Sattui, et al.. (2025). Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial. Lara D. Veeken. 64(6). 3863–3871. 3 indexed citations
6.
Segelmark, Mårten, et al.. (2024). Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden. RMD Open. 10(1). e003822–e003822. 1 indexed citations
7.
Jones, Rachel, et al.. (2024). Albuminuria after induction treatment and kidney prognosis in ANCA-associated glomerulonephritis. Clinical Kidney Journal. 18(1). sfae379–sfae379. 1 indexed citations
8.
Floßmann, Oliver, Rachel Jones, Thomas Simpson, et al.. (2024). Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. Nephrology Dialysis Transplantation. 39(9). 1473–1482. 13 indexed citations
9.
10.
Xipell, Marc, Gema M. Lledó, Allyson Egan, et al.. (2023). From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies. Autoimmunity Reviews. 22(10). 103404–103404. 27 indexed citations
11.
Cortazar, Frank B., David Jayne, Annette Bruchfeld, & Pirow Bekker. (2022). Renal Recovery for Patients With Baseline eGFR ≤20 in Avacopan ADVOCATE Trial. Journal of the American Society of Nephrology. 33(11S). 501–501. 1 indexed citations
12.
Fisk, Marie, Magnus Althage, Sven Moosmang, et al.. (2021). Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19. Pulmonary Pharmacology & Therapeutics. 69. 102035–102035. 10 indexed citations
13.
Jayne, David, Annette Bruchfeld, Lorraine Harper, et al.. (2017). Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology. 28(9). 2756–2767. 420 indexed citations breakdown →
14.
Jayne, David, Peter Höglund, Kerstin Westman, et al.. (2012). THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS. Nephrology. 17. 45–45. 4 indexed citations
15.
Casian, Alina & David Jayne. (2012). Current modalities in the diagnosis of pulmonary vasculitis. Expert Opinion on Medical Diagnostics. 6(6). 499–516. 4 indexed citations
16.
Walsh, Michael, Marcello Tonelli, David Jayne, & Braden Manns. (2007). Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis. Journal of Nephrology. 20(2). 119–129. 3 indexed citations
17.
Merkel, Peter A., David Cuthbertson, G S Hoffman, et al.. (2004). Comparison of disease activity measures for ANCA-associated vasculitis.. Oxford University Research Archive (ORA) (University of Oxford). 4 indexed citations
18.
Luqmani, Raashid, P A Bacon, Niels Rasmussen, & David Jayne. (2001). Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials. Lara D. Veeken. 40. 80–80.
19.
Jayne, David, et al.. (1999). Branch Retinal Arteriolar Occlusion Associated With Familial Factor V Leiden Polymorphism and Positive Rheumatoid Factor. Archives of Ophthalmology. 117(7). 978–978. 8 indexed citations
20.
Esnault, Vincent, et al.. (1993). Influence of Immunoadsorption on the Removal of Immunoglobulin G Autoantibodies in Crescentic Glomerulonephritis. ˜The œNephron journals/Nephron journals. 65(2). 180–184. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter A. Merkel Breakdown of academic impact, for papers by Raashid Luqmani Breakdown of academic impact, for papers by Ulrich Specks Breakdown of academic impact, for papers by J. T. Lie Breakdown of academic impact, for papers by John H. Stone Breakdown of academic impact, for papers by Ming‐Hui Zhao Breakdown of academic impact, for papers by Robert W. Lightfoot Breakdown of academic impact, for papers by E. William St. Clair Breakdown of academic impact, for papers by Munther A. Khamashta Breakdown of academic impact, for papers by Luc Mouthon
Rankless by CCL
2026